RELMADA THERAPEUTICS, INC. 8K

Relmada filed an investor presentation describing positive interim NDV‑01 bladder cancer data, planned NDV‑01 and sepranolone IND filings and registrational trials, and its June 30, 2026 cash and share position.

Relmada Therapeutics, Inc. provided a corporate presentation dated August 2026 outlining its development strategy and clinical plans for NDV-01, a sustained‑release intravesical gemcitabine/docetaxel therapy for non‑muscle invasive bladder cancer (NMIBC), and sepranolone for compulsivity-related disorders, highlighting positive Phase 2a data from the ongoing TRCG‑011 high‑risk NMIBC study, the planned U.S. IND filing and subsequent Phase 3 RESCUE registrational program for NDV‑01 targeting both intermediate‑risk adjuvant and second‑line BCG‑unresponsive CIS populations, as well as plans to file an IND by year-end 2026 and initiate a Phase 2 study in Prader‑Willi syndrome for sepranolone, alongside a financial overview showing $217.7 million in cash, cash equivalents and short‑term investments and approximately 106.7 million common shares outstanding as of June 30, 2026.

Filing Facts

CIK

1553643

Ticker

RLMD

Form

8K

Source Type

fda

Accession

0001213900-26-086190

Alert Tier

6